JARDIANCE (empagliflozin), oral antidiabetic

• JARDIANCE has a Marketing Authorisation in the treatment of type 2 diabetes mellitus in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
• The results of a study on a large population of patients at high cardiovascular risk indicate that empagliflozin does not induce an increase in cardiovascular events compared with placebo.
• These results do not make it possible to conclude with a sufficient level of evidence that empagliflozin reduces cardiovascular events and/or total mortality in patients with type 2 diabetes and high cardiovascular risk.

-